This study tests to see if TU 025 Keishi Bukuryo Gan reduces the frequency and severity of
hot flashes in post-menopausal American women. This study will also estimate the best dose
amount and determine the common short-term side effects and risks.
Menopause is a natural transition in a woman's hormonal state associated with the cessation
of ovulation and menstruation. For approximately 80% of peri-menopausal women, menopause may
be defined by the experience of uncomfortable symptoms such as hot flashes, night sweats,
dyspareunia, urinary frequency, sleep disturbance, fatigue, depression and anxiety.
Hot flashes are the most common complaint of perimenopausal and postmenopausal Western
women. Approximately 10-20% of postmenopausal women find such symptoms nearly intolerable.
Nearly one-third of postmenopausal women experience disruptive hot flashes for 5 years after
natural menopause and approximately 20% experience hot flashes for 15 years.
Menopause has been understood as an estrogen deficiency state from which women are placed at
great risk for osteoporosis, colon cancer and heart disease. For symptom management, as well
as for disease prevention, the medical response for 20 years has been hormone replacement
therapy (HRT). In recent years, as many as 38% of US women between ages 50 and 74 years
were using HRT.
For menopause hormone therapy, in 2005, counseling patients from an evidence-based
perspective means informing patients of the significantly increased risk of dementia, breast
cancer,endometrial cancer,venous thromboembolism and gallbladder disease. Additionally,
physicians must also state that hormone therapy increases the risk of cardiovascular events
(heart attack or strokes) in women with or without pre-existing heart disease. Furthermore,
well-done studies demonstrate that hormone therapy does not enhance health-related quality
For this reason, there is great interest in non-hormonal alternatives for menopausal hot
flash management. The current standard of care, based on controlled clinical trials in women
with breast cancer, is the use of SSRI anti-depressants such as venlafaxine. However, many
women seek other options.
In Japan, TJ25 Keishi Bukuryo Gan is a leading non-hormonal prescription agent for
management of menopausal hot flashes. However, no clinical data exists on its effectiveness
in American women.
This is a pilot phase II clinical study to estimate the effectiveness of TU-25 Keishi
Bukuryo Gan for reduction of both the severity and the frequency of hot flashes in healthy
postmenopausal American women. This study will also estimate the best dose and determine the
common short-term side effects and risks.
- Post-menopausal women aged 45-58 with an adequate hot flash frequency severity score.
Post-menopause is defined as amenorrhea for at least 12 months, or post-hysterectomy
for more than one year with follicle-stimulating hormone levels greater than or equal
to 40 mIU/mL and estradiol (E2) levels of less than or equal to 20 pg/mL, or greater
than two months post oophorectomy.
- All subjects must be up to date with both pap and mammogram screening by the US
Preventative Services Taskforce Guidelines for the length of the trial.
- All subjects on any prescription medication need the approval of their prescribing
physician for participation in the trial.
- Concurrent hot flash therapies (prescription medications including hormones,
antidepressants, SERMs, gabapentin or over the counter supplements)
- Moderately severe disease state(s) or diseases that affect absorption/metabolism, or
diseases that mimic menopausal hot flashes.
- Inability to swallow vitamin size pills
- Beck depression inventory score greater than 11
- Greater than 10 cigarettes per day
- Abnormal liver function
- Treated or untreated hypertension greater than 160/90.
- BMI greater than 36
- Inability to give consent or commit to the length of the trial
- Known hypersensitivity to ingredients
- Physician judgment